INVO Fertility (IVF) risk factors

52 risks, 6 new, 53 dropped, 13 reworded since the prior year. Expansion strategy now emphasizes acquiring profitable U.S. fertility clinics, but targets, financing, and integration remain uncertain.

99 risks. INVO Fertility faces substantial accumulated net losses, ongoing liquidity concerns, and a high degree of operational leverage tied to debt and acquisitions like WFI and NAYA Therapeutics. Regulatory compliance across FDA medical device standards and healthcare fraud laws significantly impacts commercialization efforts and clinical trials.